| ¿µ¹® | corticosteroid | ÇÑ±Û | ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å |
|---|---|---|---|
| ¼³¸í | ÄáÆÏÀ§¿¡ ÀÖ´Â »ï°¢»ÔÀÇ ÇüŸ¦ Áö´Ñ ±â°üÀÎ ºÎ½ÅÀÇ °ÑºÎºÐÀÎ °ÑÁú¿¡¼ ¸¸µé¾îÁö´Â ¹°Áú·Î È£¸£¸óÀÇ ÀÏÁ¾. ÄÚ¸£Æ¼°í½ºÅ×·ÎÀ̵å´Â ±× ¿ªÇÒ¿¡ µû¶ó¼ ´ÙÀ½°ú °°Àº 3°¡Áö·Î ³ª´©¾îÁø´Ù. 1.±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å(glucocorticoid)-Áö¹æÁú, ´çÁú, ´Ü¹éÁúÀÇ ´ë»ç¿¡ °ü°èÇϴ ȣ¸£¸ó. Áö¹æÁú°ú ´Ü¹éÁúÀ» ºÐÇØÇØ¼ ´çÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» ÇÏ°í ¶Ç Ã¼³»¿¡ ÀúÀåµÇ¾î ÀÖ´Â ´çÁúÀ» Ç÷¾×¼ÓÀ¸·Î ¹èÃâÇÏ´Â ¿ªÇÒÀ» Çϴ ȣ¸£¸ó. ºÎ½Å°ÑÁú¿¡¼ ¸¸µé¾îÁö´Â ´ç·ùÄÚ¸£Æ¼ÄÚÀ̵å´Â ´ëºÎºÐ ÄÚ¸£Æ¼¼Ö(cortisol)À̶ó´Â ¹°ÁúÀÌ´Ù. 2.±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵å(mineralocorticoid)-ü³»ÀÇ ÀüÇØÁú°ú ¼öºÐÀÇ Á¶Àý¿¡ °ü¿©Çϴ ȣ¸£¸ó. ÄáÆÏ¿¡ ÀÛ¿ëÇÏ¿© ¼öºÐ°ú ³ªÆ®·ýÀÇ ¹è¼³À» ¾ïÁ¦ÇÏ¿© ¼öºÐ, ³ªÆ®·ýÀÇ Ã¼³» ¾çÀ» Áõ°¡½ÃŰ´Â ¿ªÇÒÀ» ÇÑ´Ù. 3.¿¡½ºÆ®·Î°Õ, ¾Èµå·Î°Õ-¼ºÈ£¸£¸óÀ¸·Î ¼ºÀÇ ºÐȳª ¿©·¯ °¡Áö »ý½Ä¿¡ °ü·ÃµÈ ¿ªÇÒÀ» ÇÑ´Ù. ¾Ë¾ÆµÎ¾î¾ß ÇÒ °ÍÀº ºÎ½Å°ÑÁú¿¡¼ »ý»êµÈ À§ÀÇ 3°¡Áö È£¸£¸óÀº Á¤È®È÷ ±â´ÉÀÇ ±¸ºÐÀÌ ÀÖ´Â °ÍÀÌ ¾Æ´Ï°í ´Ù¸¥ È£¸£¸óÀÇ ÀÛ¿ëµµ °¡Áö°í ÀÖ´Â ¼ö°¡ ¸¹´Ù. Áï ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵嵵 ¾à°£ÀÇ ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵åÀÇ ¿ªÇÒÀÌ ÀÖ°í, ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵嵵 ¾à°£ÀÇ ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵åÀÇ ¿ªÇÒÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | urinary bladder | ÇÑ±Û | ¹æ±¤ |
|---|---|---|---|
| ¼³¸í | °ñ¹Ý°ÀÇ ¹èÂÊ¿¡ ÀÖ´Â, ¿äÀÇ ÀúÀ忪ÇÒÀ» ÇÏ´Â ±Ù¸·¼ºÀÇ ÁÖ¸Ó´Ï·Î ¿ä´Â ¿ä°üÀ¸·ÎºÎÅÍ À¯ÀÔµÇ°í ¹æ±¤Àº ´Ù½Ã ¿ÀÁÜÀ» ¿äµµ·Î ¹èÃâÇÑ´Ù. ¹æ±¤¿¡¼ ¿äµµ·Î ÀÌÇàµÇ´Â ºÎÀ§´Â ¸ð¾ç¿¡ µû¶ó »ï°¢ºÎ(trigone)À̶ó ÇÑ´Ù. ³²¼º¿¡¼´Â µÚ¿¡ Àü¸³»ù(prostate)ÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | urinary system | ÇÑ±Û | ºñ´¢±â°èÅë |
|---|---|---|---|
| ¼³¸í | ºñ´¢±â°èÅëÀ̶óÇϸé ÄáÆÏÀ¸·ÎºÎÅÍ ½ÃÀÛÇØ¼ ¿ä°ü, ¹æ±¤, ¿äµµ¿¡ À̸£´Â ÀÏ·ÃÀÇ ¿ÀÁÜ»ý¼º ¹× ÀúÀå, ¹è¼³±â°üÀ» ÀÏÄ´´Ù. ÄáÆÏÀº ±æÀÌ ¾à 2.5cm, Æø ¾à 5.1cm, µÎ²² ¾à 2.5cm, ¹«°Ô ¾à 120~160gmÀ¸·Î¼, ³»Ãø¿¡ ÄáÆÏ¹®ÀÌ ÀÖ¾î Ç÷°ü, ½Å°æ, ¿ä°üÀÌ ÃâÀÔÇϰí ÀÖ´Ù. ÄáÆÏÀº ¼ÓÁú°ú °ÑÁú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¼öÁúÀº 10~15°³ÀÇ Ãßü(¿ÀÁÜÀ» ¸ðÀ¸´Â ¿ªÇÒ)¸¦ Çü¼ºÇÏ°í °ÑÁúÀº ¾à 100¸¸°³ÀÇ ÄáÆÏ´ÜÀ§À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¿ä¼¼°üÀº Å丮ÂÊ´¢¼¼°ü, Çî·¹°í¸®, ¸ÕÂÊ´¢¼¼°ü, ÁýÇÕ°üÀ¸·Î Çü¼ºµÇ¾î ÀÖÀ¸¸ç, Ãßü¿Í ¼úÀÜ, ±ò¶§±â¸¦ °ÅÃÄ ¿ä°üÀ¸·Î ¿¬°áµÈ´Ù. ÄáÆÏÀº Ç÷¾×À» ¿©°úÇÏ¿© ½Åü ½ÅÁø´ë»çÀÇ ÃÖÁ¾»ê¹°À» ¿ÀÁÜÀÇ ÇüÅ·Π¹è¼³Çϸç, ¼¼Æ÷¿Ü¾×(extracellular fluid)ÀÇ ÀüÇØÁú³óµµ¸¦ Á¶ÀýÇÑ´Ù. ÄáÆÏ¿¡¼ Çü¼ºµÈ ¿ÀÁÜ´Â ¿ä°üÀ» °ÅÃÄ ¹æ±¤¿¡¼ ÀúÀåµÇ°í ÀÖ´Ù°¡ Àû´çÇÑ ½Ã±â°¡ µÇ¸é ¿äµµ¸¦ ÅëÇØ ¿Ü°è·Î ¹èÃâµÈ´Ù. |
||
| ¿µ¹® | urinary tract | ÇÑ±Û | ¿ä·Î |
|---|---|---|---|
| ¼³¸í | ¿ÀÁÜÀ» ¸ö ¹ÛÀ¸·Î ¹èÃâÇϱâ À§ÇÑ ±æ. ÄáÆÏ, ¿ä°ü, ¹æ±¤, ¿äµµ·Î ÀÌ·ç¾îÁ® ÀÖ´Ù. |
||
| ¿µ¹® | urinary incontinence | ÇÑ±Û | ¿ä½Ç±Ý |
|---|---|---|---|
| ¼³¸í | ¹æ±¤Á¶ÀÓ±Ù ¹× ¿äµµÁ¶ÀÓ±ÙÀÇ ¼öÀÇÀû Á¶ÀýÀÌ ¾ÈµÇ±â ¶§¹®¿¡ ¿ÀÁÜÀÌ Ç×»ó, ¶Ç´Â ¶§¶§·Î ºÒ¼öÀÇÀûÀ¸·Î ¹è¼³µÇ´Â °Í. Âü½Ç±Ý(true incontinence): ½Å°æ°èÅëÀÇ ÀÌ»ó¿¡ ÀÇÇÑ Áø¼º¿ä½Ç±Ý. ½Å°æ°èÅëÀÇ ÀÌ»óÀ̹ǷΠġ·á´Â ºÒ°¡´ÉÇÑ °æ¿ì°¡ ¸¹´Ù. ±ä¹Ú½Ç±Ý(urge incontinence): ¹æ±¤ µîÀÇ ¿°Áõ¿¡ ÀÇÇÑ ±Þ¹Ú¿ä½Ç±Ý. ¿°Áõ¿¡ ÀÇÇÑ ÀÚ±ØÁõ»óÀ¸·Î ¿°ÁõÀ» Ä¡·áÇϸé ÀÚ¿¬È÷ ¼Ò½ÇµÈ´Ù. ½ºÆ®·¹½º½Ç±Ý(stress incontinence): °ñ¹ÝÀÇ ÇØºÎÇÐÀû ÁöÁö±¸Á¶ÀÇ ¾àÈ¿¡ ÀÇÇØ ±âħ µî º¹¾ÐÀÌ Áõ°¡ÇÏ´Â »óȲ¿¡¼ ¼ø°£ÀûÀ¸·Î ¹ß»ýÇÏ´Â ¿ä½Ç±Ý. ´ë°³ ³ªÀÌ ¸¹Àº ¿©¼º¿¡¼ ¸¹À¸¸ç, ´ÙÃâ»êÀÇ °æ·ÂÀ» °¡Áö°í ÀÖ´Ù. Ä¡·á´Â ¼ö¼úÀû ¹æ¹ýÀÌ´Ù. ³Ñħ½Ç±Ý(overflow incontinence): ¹æ±¤ÀÌÇϺÎÀ§ÀÇ Æó»ö¿¡ ÀÇÇØ ¿ÀÁÜÀÌ ¹è¼³µÇÁö ¸øÇÏ°í ¹æ±¤¿¡ Àú·ùµÇ´Ù°¡ ¹æ±¤ÀÇ ÀúÀå¿ë·®À» ³Ñ´Â ¼ø°£ ÁÖüÇÏÁö ¸øÇÏ°í ³ªÅ¸³ª´Â ¿ä½Ç±Ý. |
||
| UAP | unlicensed assistive personnel; unstable angina pectoris; urinary acid phosphatase; urinary alkaline... |
|---|---|
| UCP | uncoupling protein; urinary coproporphyrin; urinary C-peptide |
| UTI | urinary tract infection; urinary trypsin inhibitor |
| CMO | Corticosteroid Methyl-Oxidase |
| 17-OHCS | 17-OH(Hydroxy)-Corticosteroid |
| 11-OHCS | 11-hydroxy-corticosteroid |
|---|---|
| 17-OHCS | 17-hydroxy-corticosteroid |
| C | Corticosteroid |
| CBG | Corticosteroid Binding Globulin |
| CR | Corticosteroid-resistant |
| corticosteroid | <drug, endocrinology, pharmacology> Any of the steroids elaborated by the adrenal cortex (excluding the sex hormones of adrenal origin) in response to the release of adrenocorticotrophin or adrenocorticotropic hormone (ACTH) by the pituitary gland, to any of the synthetic equivalents of these steroids or to angiotensin II. They are divided, according to their predominant biological activity, into three major groups: glucocorticoids (e.g. Cortisol, cortisone), chiefly influencing carbohydrate, fat and protein metabolism, mineralocorticoids (for example aldosterone), affecting the regulation of electrolyte and water balance and C19 androgens. Some corticosteroids exhibit both types of activity in varying degrees and others exert only one type of effect. The corticosteroids are used clinically for hormonal replacement therapy, for suppression of ACTH secretion by the anterior pituitary, as antineoplastic, antiallergic and anti-inflammatory agents and to suppress the immune response. Synonym: adrenocortical hormone, corticoid. (13 Nov 1997) |
|---|---|
| corticosteroid-binding globulin | <chemical> Chemical name: Transcortins (12 Dec 1998) |
| corticosteroid-binding protein | <chemical> Chemical name: Transcortins (12 Dec 1998) |
| corticosteroid cream | <drug, pharmacology> This is a large group of trade name medications that contain an anti-inflammatory steroid. These cream based medications all contain either hydrocortisone in varying concentrations or a synthetic steroid with much greater potency. This type of medications is useful in the treatment of a large number of inflammatory rashes. Caution: higher potency creams can cause side effects. Examples include hydrocortisone, dexamethasone, flunisolide, fluocinonide, fluprednisolone, Aclovate, Alphatrex, Aristocort, Betatrex, Cortone, Diprolene, Valisone, Halog, Hytone, Kenalog, Lidex, Lotrisone, Synalar, Synemol, Topicort, Vytone, Westcort and Vioform. (27 Sep 1997) |
| corticosteroid-induced acne | The exacerbation of acne after corticosteroid use is a common drug reaction seen in adolescents. Lessening the dose of the corticosteroid will often diminish this effect. (27 Sep 1997) |
| corticosteroid-induced glaucoma | <ophthalmology> Glaucoma caused by a hereditary predisposition in which local instillation of eyedrops containing corticosteroid causes increased intraocular pressure. (05 Mar 2000) |
| corticosteroid-induced striae | <dermatology> High-dose glucocorticoid therapy causes atrophy of the skin and a failure of the normal regenerative process. Purple striae often develop over the individual's trunk or thighs. The colour fades when the drug is stopped, but the dermal atrophy remains. (27 Sep 1997) |
| corticosteroid side-chain-isomerase | <enzyme> Converts 11-deoxycorticosterone to 20-hydroxy-3-oxypregn-4-en-21-al; also acts as an epimerase at c-20 Registry number: EC 5.3.1.21 Synonym: corticosteroid side chain isomerase, ccsci (26 Jun 1999) |
| antibody-coated bacteria test, urinary | Fluorescent antibody technique for visualizing antibody-bacteria complexes in urine. The presence or absence of antibody-coated bacteria in urine correlates with localization of urinary tract infection in the kidney or bladder, respectively. (12 Dec 1998) |
| anti-infective agents, urinary | Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (12 Dec 1998) |
| apex of urinary bladder | The junction of the superior and anteroinferior surfaces of the bladder, continuous above with the median umbilical ligament. Synonym: apex vesicae. (05 Mar 2000) |
| blood, urinary | Medically called haematuria, blood in the urine can be microscopic or gross. Evaluating haematuria requires consideration of the entire urinary tract. Tests used for the diagnosis of haematuria include the intravenous pyelogram (IVP), cystoscopy, and urine cytology. Management of haematuria depends upon the underlying cause. (12 Dec 1998) |
| body of urinary bladder | The portion of the bladder between the apex and fundus. Synonym: corpus vesicae urinariae. (05 Mar 2000) |
| reproductive and urinary physiology | Physiology of the human and animal body, male or female, in the reproductive process and the physiology of the urinary tract. (12 Dec 1998) |
| mucosa of urinary bladder | The inner coat of the urinary bladder. Synonym: tunica mucosa vesicae urinariae. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|